Covaxin booster dose confers long-term protection, claims Bharat Biotech
Bharat Biotech also mentioned that Covaxin was the first vaccine in India to report sustainability of immune responses six months after the second dose.
By Newsmeter Network Published on 8 Jan 2022 2:13 PM GMT
Hyderabad: Claiming promising results in booster dose trials, Hyderabad-based Bharat Biotech on January 8 said that Covaxin as a booster is safe, highly immunogenic, and has long-term protective efficacy against SARS-CoV-2.
Bharat Biotech termed Covaxin as 'the first vaccine in India to report safety and immunogenicity results from a booster clinical trial.' "The booster dose led to a pronounced increase in CD4 and CD8 responses. This may allow Covaxin to confer long-term protective efficacy against severe SARS-CoV-2," it said.
It also mentioned that Covaxin was the first vaccine in India to report sustainability of immune responses six months after the second dose.
The biotechnology company further said that the booster dose of Covaxin, the neutralization antibody titers were five times higher than after two doses. It also claimed that the frequency of adverse events was found to be lower for Covaxin when compared with vaccines produced by other companies.
"90% of recipients reported a detectable neutralizing antibody response. Both T&B cell responses were detected," it added.
